JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax

Eli Lilly is reportedly looking to get French biotech Abivax, sending the second company’s shares surging up of the J.P. Morgan Healthcare Conference 2026.

According to a study by French quality outlet La Lettre on 12 January, Eli Lilly is said to beryllium moving connected a imaginable €15bn ($17.5bn) woody for Abivax, a institution processing anti-inflammatory drugs.

Eli Lilly declined to remark connected concern improvement activity, and Abivax did not instantly respond to Pharmaceutical Technology's petition regarding the imaginable deal.

Share terms successful Paris-listed Abivax opened 17.5% up astatine €120 astatine marketplace unfastened connected 12 January, compared to marketplace adjacent of €99 connected 9 January. The biotech, which is besides listed connected the Nasdaq Global Market, has a marketplace headdress of €8.4bn.

Abivax’s pb plus is obefazimod, an orally administered tiny molecule that increases the anti-inflammatory microRNA, miR-124, successful immune cells. The therapy has demonstrated affirmative Phase III results arsenic a monotherapy successful patients with mean to severely progressive ulcerative colitis (UC). Obefazimod is besides successful Phase II objective improvement (NCT06456593) for Crohn’s disease.

In a firm update to investors, published past week, Abivax said obefazimod is "well positioned to go a aboriginal marketplace person successful the inflammatory bowel illness space”.

According to GlobalData’s Pharma Intelligence Centre, obefazimod is forecast to make planetary income of $1.8bn successful 2031. GlobalData is the genitor institution of Pharmaceutical Technology.

Reports regarding a imaginable acquisition of Abivax travel arsenic the 2026 J.P. Morgan Healthcare Conference gets underway. The lawsuit continues to beryllium a hive of dealmaking enactment crossed the pharmaceutical and biotech sectors.

2026 already looks acceptable for a beardown commencement successful the healthcare M&A space. Cancer biotech Revolution Medicines has emerged arsenic a cardinal acquisition target, with MSD reportedly successful talks to bargain the institution successful a woody worthy betwixt $28bn and $32bn.

Sign up present to person regular updates connected the latest healthcare manufacture trends emerging from the JP Morgan Healthcare Conference 2026. Sign up present to person a broad report aft the conference.

"JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.